Interferon beta-1a biosimilar - CinnaGen

Drug Profile

Interferon beta-1a biosimilar - CinnaGen

Alternative Names: CinnoVex; Rec Hu - IFN beta1a

Latest Information Update: 08 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CinnaGen
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Multiple sclerosis

Most Recent Events

  • 22 Feb 2018 CinnaGen initiates a phase III trial for Multiple sclerosis in Iran (IM) (IRCT201612306135N8)
  • 25 Jan 2017 CinnaGen plans a phase III trial for Multiple sclerosis in Iran (IM) (IRCT201612306135N8)
  • 22 Jun 2016 No recent reports on development identified - Registered for Multiple sclerosis in Azerbaijan (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top